CJC-1295 DAC
Also known as: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
Key Facts: CJC-1295 DAC
- Category
- Growth Hormone
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Research compound
- Administration
- Subcutaneous injection
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Human Trials
- Duration
- 8-12 weeks typical
What to Expect
A long-acting GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation for days with single injection.
Mechanism of Action
CJC-1295 DAC contains a reactive linker that binds to albumin after injection. This extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation.
Research Summary
Studies show sustained 2-10 fold increase in GH levels lasting several days. Single weekly injection maintains elevated IGF-1. Less physiologic than pulsatile protocols but more convenient.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
1-2 mg weekly
Some use twice weekly
Duration
8-12 weeks typical
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Facial flushing
- ●Water retention
- ●Headache
- ●Side effects persist longer due to 8-day half-life
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Clinical trial discontinued
References
Related Peptides
Peptides commonly compared with CJC-1295 DAC or used in similar applications.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Growth HormoneMK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Not a peptide technically, but frequently discussed alongside GH peptides due to similar effects.
Growth HormoneCJC-1295
Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Growth HormoneTesamorelin
FDAAn FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. One of the few peptides with FDA approval.
Growth HormoneGHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
Growth HormoneGHRP-2
Clinical TrialsA synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Growth HormoneWant updates on CJC-1295 DAC research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.